Noopur Raje, MD

Articles by Noopur Raje, MD

A panel of 4 experts on multiple myeloma

Impact of T-cell Affinity in Bispecific Therapy in R/R MM

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

October 4th 2024

Noopur Raje, MD, discusses the role of T-cell affinity in bispecific therapy for patients with relapsed/refractory multiple myeloma and how it impacts treatment practices.

Overview of Recent Updates in Bispecific Therapy in R/R MM

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

October 4th 2024

The panel discusses the benefits of having multiple BCMA-targeting bispecifics available for patients with relapsed/refractory multiple myeloma.

Implications of Combination Regimens for R/R MM

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

September 27th 2024

Rafael Fonseca, MD, discusses the role of bispecifics in relapsed/refractory multiple myeloma and the implications of incorporating them into combination regimens.

Overview of RedirecTT-1, MagnetisMM-30 and MagnetisMM-5

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

September 27th 2024

Noopur Raje, MD, reviews clinical research on elranatamab combination therapy in patients with relapsed/refractory multiple myeloma.

Evaluating Combination Strategies in R/R MM: TRIMM-2, TRIMM-3, MajesTEC-3

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

September 20th 2024

Focusing on clinical trials evaluating combination strategies with bispecifics, Larysa J. Sanchez, MD, discusses the TRIMM-2, TRIMM-3, and MajesTEC-3 studies.

Overview of MonumenTAL-2 and MonumenTAL-3

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

September 20th 2024

Rafael Fonseca, MD, discusses the MonumenTAL-2 and MonumenTAL-3 clinical trials investigating talquetamab combination strategies in relapsed/refractory multiple myeloma.

Broader Implications and Current Trials of GPRC5D-Targeted Treatments in Relapsed/Refractory Multiple Myeloma

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

September 13th 2024

Hematologist-oncologists discuss GPRC5D-targeting treatments that are currently in development for patients with relapsed/refractory multiple myeloma.

MonumenTAL-1: Efficacy and Safety Data

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

September 13th 2024

Noopur Raje, MD, shares clinical perspectives on her experience treating patients with prior BCMA bispecific exposure and provides insights on adverse event management practices in patients receiving talquetamab.

Long-Term Follow-Up of MonumenTAL-1

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

September 6th 2024

Larysa J. Sanchez, MD, discusses recent efficacy data presented at EHA 2024 from the long-term follow-up results of the phase 1/2 MonumenTAL-1 study investigating talquetamab in relapsed/refractory multiple myeloma.

Significance of GPRC5D as a Target for R/R MM

ByAjai Chari, MD,Noopur Raje, MD,Rafael Fonseca, MD,Larysa Sanchez, MD

September 6th 2024

A panel of experts on multiple myeloma discuss the importance of GPRC5D as a target of interest in relapsed/refractory disease and discuss their experiences with talquetamab in clinical practice.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

ByRahul Banerjee, MD, FACP,Noopur Raje, MD

September 2nd 2024

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing AEs Associated With Bispecifics in RRMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

July 19th 2022

Closing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.

Bispecific Antibodies in the Treatment of RRMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

July 11th 2022

Comprehensive perspectives on the role of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma.

CAR-T Therapies Therapy in RRMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

July 11th 2022

A brief review of the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Patient Profile 3: A 57-Year-Old Woman With Triple-Class Refractory MM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

July 6th 2022

Moving to the last patient profile, expert panelists discuss a patient with triple-class refractory multiple myeloma managed with BCMA-targeting bispecific therapy.

Treating Transplant-Ineligible NDMM With High-Risk Cytogenetics

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

July 6th 2022

Shared insight on the selection of therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma and high-risk cytogenetics.

Selection and Duration of Therapy in Transplant-Ineligible NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 29th 2022

Expert panelists consider which regimen they would use, and for what duration, in the setting of transplant-ineligible, newly diagnosed multiple myeloma.

Patient Profile 2: A 72-Year-Old With Transplant-Ineligible NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 29th 2022

The panel moves on to review the profile of a patient with transplant-ineligible, newly diagnosed multiple myeloma managed with dara-Rd on the MAIA trial.

Duration of Therapy in NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 22nd 2022

Before closing their discussion on transplant-eligible, newly diagnosed multiple myeloma, experts consider duration of therapy in this setting.

Selecting Appropriate Therapy for Transplant-Eligible NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 22nd 2022

Panelists briefly review factors they use to select induction therapy for patients with transplant-eligible, newly diagnosed multiple myeloma.

Quadruplet Vs Triplet Induction Regimens for Transplant-Eligible NDMM

ByNoopur Raje, MD,Jacob Laubach, MD,Omar Nadeem, MD,Andrew J. Yee, MD

June 15th 2022

Shared insight on approved quadruplet vs triplet induction regimens for patients with transplant-eligible, newly diagnosed multiple myeloma, evaluated in the GRIFFIN, MASTER and GMMG-HD7 trials.